Abstract：Objective: To explore the diagnostic accuracy of CT-guided percutaneous transthoracic needle biopsy (PTNB) for non-small cell lung cancer (NSCLC) and its influencing factors. Methods: A total of 98 patients with NSCLC treated in the hospital were enrolled as the research subjects between May 2020 and May 2022. All underwent PTNB. Taking the results of postoperative pathological examination as the golden standard, diagnostic results of PTNB for NSCLC were statistically analyzed, and the influencing factors of diagnostic accuracy were analyzed. Results: The diagnostic accuracy of PTNB for NSCLC was 87.76% (86/98), and the accuracy rates of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and adenosquamous carcinoma were 91.53% (54/59), 93.94% (31/33), 0.00% (0/2) and 25.00% (1/4), respectively. The results of univariate analysis showed that there was no significant difference in gender, age, calcification, size of biopsy tissues or biopsy frequency between accuracy group and non-accuracy group (P>0.05), but there were significant differences in lesion sites, lesion size, distance between lesion and chest walls, necrosis and puncture depth (P<0.05). The results of multivariate analysis showed that lesions at inferior lobe, lesion <2cm, the distance between lesions and chest walls <2cm and necrosis were independent influencing factors of diagnostic accuracy rate. Conclusion: PTNB has high diagnostic value for adenocarcinoma and squamous cell carcinoma, but has low diagnostic value for large cell carcinoma and adenosquamous carcinoma. The independent influencing factors of diagnostic accuracy rate include lesions at inferior lobe, lesions <2cm, the distance between lesions and chest walls <2cm and necrosis. Targeted measures is beneficial to increase diagnostic accuracy rate.
[1] Zhuang Q,Huang Y,Hong Y,et al.Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling[J].Investig Med,2022,70(6):1358-1364. [2] Lanchard D,Paz-Ares L,Vansteenkiste JF,et al.Five-year survival outcomes from the PACIFIC trial:durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer[J].Clin Oncol,2022,40(12):1301-1311. [3] 吴莹莹,周江云.阿帕替尼联合调强放疗治疗中晚期非小细胞肺癌的疗效分析[J].中国医师杂志,2020,22(2):289-292. [4] Si H,Du D,Li W,et al.Sputum-based tumor fluid biopsy:isolation and high-throughput single-cell analysis of exfoliated tumor cells for lung cancer diagnosis[J].Anal Chem,2021,93(30):10477-10486. [5] Gao Z,Yuan H,MaoY,et al.In situ detection of plasma exosomal microRNA for lung cancer diagnosis using duplex-specific nuclease and MoS2nanosheets[J].Analyst,2021,146(6):1924-1931. [6] Youn B,Trikalinos NA,Mor V,et al.Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer[J].Cancer,2020,126(5):978-985. [7] Stamatis G,Muller S,Weinreich G,et al.Significantly favourable outcome for patients with non-small-cell lung cancer stage IIIA/IIIB and single-station persistent N2 (skip or additionally N1) disease after multimodality treatment[J].Eur Cardiothorac Surg,2022,61(2):269-276. [8] Chen J,Zeng H,Zhang C,et al.Lung cancer diagnosis using deep attention-based multiple instance learning and radiomics[J].Med Phys,2022,49(5):3134-3143. [9] Srinivasan S,Wilseck ZM,Linzey JR,et al.Multiphase CT angiography for evaluation and diagnosis of complex spinal dural arteriovenous fistula[J].Can Neurol Sci,2020,47(5):681-682. [10] 凤婧,颜浩,韩娟,等.CT引导下经皮肺穿刺活检术在肺部占位性病变诊断中的临床应用[J].重庆医学,2022,51(4):607-611617.
2023, Vol. 29 
冀公网安备13080202000786号